the aid library

LIST OPTIONS

Filter

8954

Financing Agenda 2030

Burgess B., Custer J., Custer S. AidData (2023) CC

To realize Agenda 2030, aid agencies, private philanthropies, and their partners in the Global South need better data to monitor how official development finance (ODF) dollars advance the Sustainable Development Goals (SDGs) and avoid missing the mark. In this report, we summarize the results of a n... more

Download (137)

View PDF (83)

Neglected Disease Research and Development: The Higher Cost of Lower Funding

G-Finder (2023) CC

Each year since 2007, G-FINDER has provided policy-makers, donors, researchers and industry with a comprehensive analysis of global investment into research and development of new products to prevent, diagnose, control or cure neglected diseases in low- and middle-income countries, making it the go... more

Download (130)

View PDF (285)

Government Health Spending Outlook - Projections Through 2029: Diverging Fiscal Pressures, Uneven Constraints

The International Bank for Reconstruction and Development The World Bank (2024) CC

This paper examines the implications of the IMF’s April 2024 macro-fiscal forecast updates on government health expenditure (GHE) across 170 economies through 2029, covering nearly all years remaining to achieve the Sustainable Development Goals (SDGs). The findings reveal wide disparities in gove... more

Download (72)

View PDF (58)

Health Taxes in the Polycrisis Era

Klemperer K., Baker P. Center for Global Development (2024) CC

In 2019, the Task Force on Fiscal Policy for Health concluded that taxes on tobacco, alcohol, and sugar-sweetened beverages were a highly effective but greatly underused policy tool to reduce consumption, save lives, and raise domestic resources. The Task Force estimated that if all countries increa... more

Download (808)

View PDF (1154)

Expanding the Roles of Nurses in Primary Health Care

Pan American Health Organization (PAHO), World Health Organization - Regional Office for the Americas (WHO) (2018) C_WHO

[Preface]. For more than forty years Primary Health Care (PHC) has been recognized as the cornerstone of an effective and responsive health system. The Alma-Ata Declaration of 1978 reaffirmed the right to the highest attainable level of health, with equity, solidarity and the right to health as its ... more

Download (269)

View PDF (246)

Unintended Pregnancy and Induced Abortion In Burkina Faso: Causes and Consequences

Bankole A., Hussain R., Sedgh G. et. al. Guttmacher Institute (2014) C2

Induced abortion is permitted in Burkina Faso only to save the life and protect the health of a pregnant woman, or in cases of rape, incest, and severe fetal impairment. As a result, the vast majority of women who end unintended pregnancies do so in secrecy, out of fear of prosecution and to avoi... more

Download (257)

View PDF (262)

Leprosy Programme and Transmission Assessment - Tool accompanying the Technical guidance on interruption of transmission and elimination of leprosy

World Health Organization WHO (2023) C_WHO

The Leprosy Programme and Transmission Assessment (LPTA) is an activity that is carried out by internal teams towards the end of Phase 1 (see Leprosy Elimination Framework in the Annex) when a subnational jurisdiction (typically second-tier) reaches the milestone for interruption of transmission, i.... more

External Link

Worldwide Control and Management of Chagas Disease in a New Era of Globalization: a Close Look at Congenital Trypanosoma cruzi Infection.

Abras A., Ballart C., Fernández-Arévalo A., et al. Clinical Microbiology Reviews (2022) CC

April 2022 Volume 35 Issue 2 e00152-21 Population movements have turned Chagas disease (CD) into a global public health problem. Despite the successful implementation of subregional initiatives to control vectorial and transfusional Trypanosoma cruzi transmission in Latin American settings where t... more

Download (254)

View PDF (302)

Checklist for hospitals preparing for the reception and care of coronavirus 2019 (COVID-19) patients
recommended

European Centre for Disease Prevention and Control ECDC (2020) C1

This checklist has been developed to support hospital preparedness for the management of COVID-19 patients. Elements to be assessed have been divided into the following areas: Establishment of a core team and key internal and external contact points Human, material and facility capacit... more

Download (401)

View PDF (345)

Monitoring and surveillance of antimicrobial resistance in bacteria from healthy food animals intended for consumption

Food and Agriculture Organization of the United Nations FAO (2019) C2

The animal health subsector within the agriculture sector is the gatekeeper of antimicrobial resistance (AMR) in livestock, aquaculture, animal products, and the immediate animal environment. In support of member countries taking responsibility for and moving forward with putting AMR monitoring and ... more

Download (454)

View PDF (687)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (221)

View PDF (382)

El Salvador's Health Emergency Appeal 2023

World Health Organisation (WHO) (2023) C_WHO

The recurrence of severe climate events combined with economic, social, and institutional fragilities leave El Salvador in an utterly critical humanitarian situation and highly vulnerable. Located in a disaster-prone subregion, El Salvador is among the 20 countries at the highest risk of disasters w... more

External Link

Vector-borne diseases: a handbook for pharmacists - Disease prevention, control, management and treatment

Gromek K., Hung M., Montero N. et al International Pharmaceutical Federation FIP (2020) C2

The Pharmaceutical Forum of the Americas (PFA) has previously published guidelines and organised campaigns for community pharmacists on the prevention, detection and control of arbovirus infections in 2018 with a grant from the FIP Foundation for Pharmacy Education and Research. Building on that exp... more

Download (277)

View PDF (332)

ATENCIÓN A NIÑOS Y NIÑAS SOBREVIVIENTES DE ABUSOS SEXUALES DIRECTRICES

UN Children's Fund UNICEF (2024) CC

Produced by UNICEF and IRC, with the support of the German Corporation for International Cooperation GmbH (GIZ) and the generous funding from the German Federal Ministry of Economic Cooperation and Development (BMZ), the Caring for Child Survivors of Sexual Abuse (CCS) Resource Package (Second Editi... more

Download (302)

View PDF (445)

Caring for child survivors of sexual abuse Resource Package
recommended

UN Children's Fund UNICEF (2024) CC

Download (224)

View PDF (246)

Containment Plan for Large Outbreaks Novel Coronavirus Disease 2019 (COVID-19)

Ministry of Health and Family Welfare Government of India (2020) C2

On 31st December 2019, the World Health Organization (WHO) China Country Office was informed of cases of pneumonia of unknown etiology (unknown cause) detected in Wuhan City, Hubei Province of China. On 7th January 2020, Chinese authorities identified a new strain of Coronavirus as the causative age... more

Download (1394)

View PDF (1778)

The economic impact of shelter assistance in post-disaster settings

Stephen Sheppard, Richard Hill CHF International, USAID (2005)

This report addresses the impact of emergency shelter programs in the development of post-relief economies and in building incomes of affected populations. It provides a review and analysis of the available literature relevant to understanding the economic impact of emergency shelter programs, addit... more

Download (1181)

View PDF (2211)

Synchronizing Gender Strategies: A Cooperative Model for Improving Reproductive Health and Transforming Gender Relations

Margaret E. Greene and Andrew Levack IGWG (2010)

This publication makes the case for working with men and women, boys and girls, together in an intentional and mutually reinforcing way that challenges gender norms in the pursuit of improved health and gender equality. In addition to providing a definition for the new concept of gender synchronizat... more

Download (315)

View PDF (318)

Government policy interventions to reduce human antimicrobial use: A systematic review and evidence map

Van Katwyk, S. R.; Grimshaw, J. M.; et al (2019) C2

BACKGROUND: Growing political attention to antimicrobial resistance (AMR) offers a rare opportunity for achieving meaningful action. Many governments have developed national AMR action plans, but most have not yet implemented policy interventions to reduce antimicrobial overuse. A systematic evidenc...e map can support governments in making evidence-informed decisions about implementing programs to reduce AMR, by identifying, describing, and assessing the full range of evaluated government policy options to reduce antimicrobial use in humans. METHODS AND FINDINGS: Seven databases were searched from inception to January 28, 2019, (MEDLINE, CINAHL, EMBASE, PAIS Index, Cochrane Central Register of Controlled Trials, Web of Science, and PubMed). We identified studies that (1) clearly described a government policy intervention aimed at reducing human antimicrobial use, and (2) applied a quantitative design to measure the impact. We found 69 unique evaluations of government policy interventions carried out across 4 of the 6 WHO regions. These evaluations included randomized controlled trials (n = 4), non-randomized controlled trials (n = 3), controlled before-and-after designs (n = 7), interrupted time series designs (n = 25), uncontrolled before-and-after designs (n = 18), descriptive designs (n = 10), and cohort designs (n = 2). From these we identified 17 unique policy options for governments to reduce the human use of antimicrobials. Many studies evaluated public awareness campaigns (n = 17) and antimicrobial guidelines (n = 13); however, others offered different policy options such as professional regulation, restricted reimbursement, pay for performance, and prescription requirements. Identifying these policies can inform the development of future policies and evaluations in different contexts and health systems. Limitations of our study include the possible omission of unpublished initiatives, and that policies not evaluated with respect to antimicrobial use have not been captured in this review. CONCLUSIONS: To our knowledge this is the first study to provide policy makers with synthesized evidence on specific government policy interventions addressing AMR. In the future, governments should ensure that AMR policy interventions are evaluated using rigorous study designs and that study results are published. more

Checklist for hospitals preparing for the reception and care of coronavirus 2019 (COVID-19) patients recommended

Caring for child survivors of sexual abuse Resource Package recommended

Checklist for hospitals preparing for the reception and care of coronavirus 2019 (COVID-19) patients
recommended

Caring for child survivors of sexual abuse Resource Package
recommended